Cita APA (7a ed.)

Chapman, A., Schurer, M., Weijers, L., Omar, A., Lee, H., Weidenfeller, A. Z., . . . Schneider-Gold, C. (2021). Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): Outcomes of treatment impact using a European Delphi panel. BMC.

Cita Chicago Style (17a ed.)

Chapman, Ann-Marie, Marieke Schurer, Laure Weijers, Amer Omar, Hiba Lee, Alla Zozulya Weidenfeller, Crispin Ellis, Shaneil Sonecha, y Christiane Schneider-Gold. Improving the Understanding of How Patients with Non-dystrophic Myotonia Are Selected for Myotonia Treatment with Mexiletine (NaMuscla): Outcomes of Treatment Impact Using a European Delphi Panel. BMC, 2021.

Cita MLA (8a ed.)

Chapman, Ann-Marie, et al. Improving the Understanding of How Patients with Non-dystrophic Myotonia Are Selected for Myotonia Treatment with Mexiletine (NaMuscla): Outcomes of Treatment Impact Using a European Delphi Panel. BMC, 2021.

Precaución: Estas citas no son 100% exactas.